United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - intravenous adenosine injection is indicated for the following: conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenosine injection administration. it is important to be sure the adenosine injection solution actually reaches the systemic circulation (see dosage and administration). adenosine injection does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine injection administration. intravenous adenosine injection is contraindicated in: second- or third-degree a-v block (except in patients with a functioning artificial pacemaker). sinus node disease, such as sick sinus syndrome or

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j) - thiamine hydrochloride injection is effective for the treatment of thiamine deficiency or beriberi whether of the dry (major symptoms related to the nervous system) or wet (major symptoms related to the cardiovascular system) variety. thiamine hydrochloride injection should be used where rapid restoration of thiamine is necessary, as in wernicke's encephalopathy, infantile beriberi with acute collapse, cardiovascular disease due to thiamine deficiency, or neuritis of pregnancy if vomiting is severe. it is also indicated when giving iv dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure. thiamine hydrochloride injection is also indicated in patients with established thiamine deficiency who cannot take thiamine orally due to coexisting severe anorexia, nausea, vomiting, or malabsorption. thiamine hydrochloride injection is not usually indicated for conditions of decreased oral intake or decreased gastrointestinal absorption, because multiple vitamins should usually be given. a history of sensitivity to thiamine or to any of the ingredients in this drug is a contraindication. (see warnings for further information.)

United States - English - NLM (National Library of Medicine)

hf acquisition co. llc, dba healthfirst - promethazine hydrochloride (unii: r61zeh7i1i) (promethazine - unii:ff28ejq494) - promethazine hydrochloride injection is indicated for the following conditions: amelioration of allergic reactions to blood or plasma. in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled. for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. for sedation and relief of apprehension and to produce light sleep from which the patient can be easily aroused. active treatment of motion sickness. prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. as an adjunct to analgesics for the control of postoperative pain. preoperative, postoperative, and obstetric (during labor) sedation. intravenously in special surgical situations, such as repeated bronchoscopy, ophthalmic surgery, and poor-risk patients, with reduced amounts of meperidine or other narcotic analgesic as an adjunct to anesthesia and analgesia. children less than 2 years of age promethazine hydrochloride injection is contraindicated for use in pediatric patients less than two years of age due to the risk of respiratory depression (see warnings - respiratory depression). comatose state promethazine hydrochloride injection is contraindicated in comatose states. intra-arterial injection under no circumstances should promethazine hydrochloride injection be given by intra-arterial injection due to the likelihood of severe arteriospasm and the possibility of resultant gangrene (see warnings - severe tissue injury, including gangrene). subcutaneous injection promethazine hydrochloride injection should not be given by the subcutaneous route because evidence of chemical irritation has been noted, and necrotic lesions have resulted following subcutaneous injection. the preferred parenteral route of administration is by deep intramuscular injection. idiosyncratic reaction or hypersensitivity promethazine hydrochloride injection is contraindicated in patients who have demonstrated an idiosyncratic reaction or hypersensitivity to promethazine or other phenothiazines.

United States - English - NLM (National Library of Medicine)

hf acquisition co. llc, dba healthfirst - promethazine hydrochloride (unii: r61zeh7i1i) (promethazine - unii:ff28ejq494) - promethazine hydrochloride injection is indicated for the following conditions: amelioration of allergic reactions to blood or plasma. in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled. for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. for sedation and relief of apprehension and to produce light sleep from which the patient can be easily aroused. active treatment of motion sickness. prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. as an adjunct to analgesics for the control of postoperative pain. preoperative, postoperative, and obstetric (during labor) sedation. intravenously in special surgical situations, such as repeated bronchoscopy, ophthalmic surgery, and poor-risk patients, with reduced amounts of meperidine or other narcotic analgesic as an adjunct to anesthesia and analgesia. children less than 2 years of age promethazine hydrochloride injection is contraindicated for use in pediatric patients less than two years of age due to the risk of respiratory depression (see warnings - respiratory depression). comatose state promethazine hydrochloride injection is contraindicated in comatose states. intra-arterial injection under no circumstances should promethazine hydrochloride injection be given by intra-arterial injection due to the likelihood of severe arteriospasm and the possibility of resultant gangrene (see warnings - severe tissue injury, including gangrene). subcutaneous injection promethazine hydrochloride injection should not be given by the subcutaneous route because evidence of chemical irritation has been noted, and necrotic lesions have resulted following subcutaneous injection. the preferred parenteral route of administration is by deep intramuscular injection. idiosyncratic reaction or hypersensitivity promethazine hydrochloride injection is contraindicated in patients who have demonstrated an idiosyncratic reaction or hypersensitivity to promethazine or other phenothiazines.

United States - English - NLM (National Library of Medicine)

hf acquisition co. llc, dba healthfirst - verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - verapamil hydrochloride injection, usp is indicated for the following: • rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (wolff-parkinson-white [w-p-w] and lown-ganong- levine [l-g-l] syndromes). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver) should be attempted prior to verapamil hydrochloride administration. • temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation except when the atrial flutter and/or atrial fibrillation are associated with accessory bypass tracts (wolff-parkinson-white (w-p-w) and lown-ganong-levine (l-g-l) syndromes). in controlled studies in the united states, about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous verapamil hydrochloride. uncontrolled studies reported in the world literature describe a conversion rate of about 80%. about 70% of patients with atrial flutter and/or fibrillation with a faster ventricular rate respond with a decrease in ventricular rate of at least 20%. conversion of atrial flutter or fibrillation to sinus rhythm is uncommon (about 10%) after verapamil hydrochloride and may reflect the spontaneous conversion rate, since the conversion rate after placebo was similar. slowing of the ventricular rate in patients with atrial fibrillation/flutter lasts 30 to 60 minutes after a single injection. because a small fraction (<1%) of patients treated with verapamil hydrochloride respond with life-threatening adverse responses (rapid ventricular rate in atrial flutter/fibrillation, and an accessory bypass tract, marked hypotension, or extreme bradycardia/asystole − see contraindications and warnings), the initial use of verapamil hydrochloride injection should, if possible, be in a treatment setting with monitoring and resuscitation facilities, including d.c.-cardioversion capability (see adverse reactions, suggested treatment of acute cardiovascular adverse reactions). as familiarity with the patient's response is gained, use in an office setting may be acceptable. cardioversion has been used safely and effectively after verapamil hydrochloride injection. verapamil hydrochloride injection is contraindicated in: 1. severe hypotension or cardiogenic shock. 2. second- or third-degree av block (except in patients with a functioning artificial ventricular pacemaker). 3. sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker). 4. severe congestive heart failure (unless secondary to a supraventricular tachycardia amenable to verapamil therapy). 5. patients receiving intravenous beta-adrenergic blocking drugs (e.g., propranolol). intravenous verapamil and intravenous beta-adrenergic blocking drugs should not be administered in close proximity to each other (within a few hours), since both may have a depressant effect on myocardial contractility and av conduction. 6. patients with atrial flutter or atrial fibrillation and an accessory bypass tract (e.g., wolff- parkinson-white, lown-ganong-levine syndromes) are at risk to develop ventricular tachyarrhythmia including ventricular fibrillation if verapamil is administered. therefore, the use of verapamil in these patients is contraindicated. 7. ventricular tachycardia: administration of intravenous verapamil to patients with wide-complex ventricular tachycardia (qrs ≥ 0.12 sec) can result in marked hemodynamic deterioration and ventricular fibrillation. proper pretherapy diagnosis and differentiation from wide-complex supraventricular tachycardia is imperative in the emergency room setting. 8. known hypersensitivity to verapamil hydrochloride.

United States - English - NLM (National Library of Medicine)

hf acquisition co. llc, dba healthfirst - water (unii: 059qf0ko0r) (water - unii:059qf0ko0r) - this parenteral preparation is indicated only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection, according to instructions of the manufacturer of the drug to be administered. sterile water for injection, usp must be made approximately isotonic prior to use.

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok) - 50% dextrose injection is indicated in the treatment of insulin hypoglycemia (hyperinsulinemia or insulin shock) to restore blood glucose levels. the solution is also indicated, after dilution, for intravenous infusion as a source of carbohydrate calories in patients whose oral intake is restricted or inadequate to maintain nutritional requirements. slow infusion of hypertonic solutions is essential to insure proper utilization of dextrose and avoid production of hyperglycemia. a concentrated dextrose solution should not be used when intracranial or intraspinal hemorrhage is present, nor in the presence of delirium tremens if the patient is already dehydrated. dextrose injection without electrolytes should not be administered simultaneously with blood through the same infusion set because of the possibility that pseudoagglutination of red cells may occur.

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - midazolam hydrochloride (unii: w7ttw573jj) (midazolam - unii:r60l0sm5bc) - midazolam injection is indicated: intramuscularly or intravenously for preoperative sedation/anxiolysis/amnesia; intravenously as an agent for sedation/anxiolysis/amnesia prior to or during diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography, cardiac catheterization, oncology procedures, radiologic procedures, suture of lacerations and other procedures either alone or in combination with other cns depressants; intravenously for induction of general anesthesia, before administration of other anesthetic agents. with the use of narcotic premedication, induction of anesthesia can be attained within a relatively narrow dose range and in a short period of time. intravenous midazolam can also be used as a component of intravenous supplementation of nitrous oxide and oxygen (balanced anesthesia); continuous intravenous infusion for sedation of intubated and mechanically ventilated patients as a component of anesthesia or during treatment

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - phenylephrine hydrochloride (unii: 04ja59tnsj) (phenylephrine - unii:1ws297w6mv) - phenylephrine hydrochloride is an alpha-1 adrenergic receptor agonist indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation, in such settings as septic shock or anesthesia. the use of phenylephrine hydrochloride is contraindicated in patients with: hypersensitivity to it or any of its components 8.1 pregnancy pregnancy category c animal reproduction studies have not been conducted with intravenous phenylephrine. it is also not known whether phenylephrine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. phenylephrine hydrochloride should be given to a pregnant woman only if clearly needed. 8.2 labor and delivery the most common maternal adverse reactions reported in studies of phenylephrine use during neuraxial anesthesia during cesarean delivery include nausea and vomiting, which are commonly associated with hypotension, bradycardia, reactive hypertension, and transient arrhythmias. phenylephrine does not appear to cause a decrease in placental perfusion sufficient to alter either the neonate apgar scores or blood-gas status. 8.3 nursing mothers it is not known whether this drug is excreted in human milk. 8.4 pediatric use safety and effectiveness in pediatric patients have not been established. 8.5 geriatric use clinical studies of phenylephrine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. 8.6 hepatic impairment in patients with liver cirrhosis [child pugh class a (n=3), class b (n=5) and class c (n=1)], dose-response data indicate decreased responsiveness to phenylephrine. consider using larger doses than usual in hepatic impaired subjects. 8.7 renal impairment in patients with end stage renal disease (esrd) undergoing hemodialysis, dose-response data indicates increased responsiveness to phenylephrine. consider using lower doses of phenylephrine hydrochloride in esrd patients.

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - water (unii: 059qf0ko0r) (water - unii:059qf0ko0r) - this parenteral preparation is indicated only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection, according to instructions of the manufacturer of the drug to be administered. sterile water for injection, usp must be made approximately isotonic prior to use.